safe
effect
vaccin
felin
leukemia
primari
goal
research
studi
felin
leukemia
viru
felv
sinc
earli
emphasi
gener
follow
identif
felin
leukemia
viral
induc
diseas
jarrett
et
al
isol
viral
strain
kawakami
et
al
rickard
et
al
late
need
exist
felv
vaccin
sinc
viru
attend
associ
syndrom
repres
lead
caus
cat
mortal
worldwid
januari
commerci
vaccin
leukocel
norden
laboratori
lincoln
ne
licens
use
usa
use
basi
prototyp
vaccin
develop
ohio
state
univers
lewi
et
al
prototyp
contain
felv
antigen
releas
lymphoid
cell
persist
infect
kawakami
isol
felv
felvassoci
protein
found
noninfecti
capabl
produc
immun
respons
without
immunosuppress
patholog
characterist
live
attenu
salerno
et
al
kill
felv
order
obtain
commerci
licens
studi
vaccin
efficaci
perform
report
continu
research
improv
vaccin
gener
new
data
explor
variou
secondari
issu
includ
possibl
immunosuppress
follow
vaccin
b
protect
establish
latent
felv
infect
upon
viru
exposur
c
immunogen
altern
rout
administr
clinic
perform
highrisk
environ
e
develop
cytotox
antibodi
follow
vaccin
review
new
inform
present
well
establish
demonstr
laboratori
math
et
al
math
et
al
felv
envelop
protein
common
retrovirus
profoundli
suppress
felin
cellular
immun
shown
exampl
purifi
inhibit
number
normal
immun
function
cell
type
vivo
vitro
hebebrand
et
al
olsen
et
al
math
et
al
math
et
al
felv
protein
effect
immunosuppress
envelop
protein
present
form
felin
leukemia
vaccin
establish
lewi
et
al
show
cat
respond
immunolog
p
vaccin
studi
perform
determin
presenc
detriment
effect
upon
immun
system
host
howev
avenu
inquiri
reliabl
shown
vaccin
produc
immunosuppress
effect
upon
lymphocyt
function
first
vaccin
impair
lymphocyt
blastogenesi
second
leukocel
given
concurr
felin
vaccin
cat
respond
immunolog
immun
agent
administ
indic
although
present
must
altern
precursor
form
induc
immunosuppress
patholog
associ
process
form
studi
conduct
determin
leukocelr
similar
effect
lymophocyt
blastogen
show
vaccin
effect
lymphocyt
mitogenesi
one
studi
dilut
unadjuv
solubl
vaccin
protein
combin
vitro
concanavalin
astimul
lymphocyt
vaccin
protein
signific
effect
simul
growth
cat
lymphocyt
compar
control
sampl
tabl
similar
test
use
whole
viru
caus
profound
suppress
tcell
mitogenesi
hebebrand
et
al
second
test
cat
vaccin
twice
concentr
adjuv
vaccin
shown
tabl
lymphocyt
cat
show
chang
lbt
lymphocyt
blast
transform
respons
compar
preand
postvaccin
valu
lbt
valu
differ
appreci
nonvaccin
cat
studi
suggest
although
antigen
site
exist
within
leukocel
prepar
protein
activ
suppress
form
previou
studi
found
level
low
g
math
et
al
suppress
protein
present
level
g
addit
inform
seen
studi
show
leukocel
given
concurr
modifi
live
viru
mlv
inactiv
rabi
vaccin
combin
mlv
felin
panleukopeniafelin
calicivirusfelin
rhinotrach
vaccin
caus
loss
amnest
respons
immun
agent
exampl
cat
immun
histori
felv
rabi
viru
inocul
concurr
leukocel
mlv
rabi
vaccin
within
week
test
cat
develop
increas
mean
antibodi
level
increas
mean
focma
felin
oncornaviru
membran
antigen
antibodi
titer
similar
pattern
serolog
respons
occur
follow
concurr
administr
leukocelr
routin
use
felin
vaccin
previous
shown
interfer
antivir
antitumor
respons
immunosuppress
occur
rapidli
introduc
host
math
et
al
therefor
postvaccin
sero
logic
respons
felv
heterolog
vaccin
signific
indic
absenc
immun
interfer
follow
administr
leukocel
recent
studi
henderson
et
al
new
light
shed
protein
may
acquir
immunosuppress
properti
retroviru
envelop
protein
precursor
form
process
virion
assembl
matur
one
structur
chang
occur
cleavag
cellular
enzym
peptid
precursor
molecul
take
place
viral
protein
produc
transport
outer
cellular
membran
thu
prior
viru
assembl
undergo
proteolyt
process
event
may
prove
necessari
becom
immunosuppress
moieti
present
within
vaccin
may
unprocess
form
thu
allow
antibodi
develop
without
immunosuppress
effect
mastro
et
al
shown
vaccin
cat
respond
differ
viral
antigen
vaccin
prepar
found
whole
viru
saw
envelop
felv
associ
protect
present
virion
respond
strongli
challeng
suggest
moieti
vaccin
similar
differ
found
matur
virion
vaccin
may
induc
primari
immun
challeng
produc
strong
amnest
respons
similar
mechan
may
occur
alter
immatur
form
present
vaccin
induc
antibodi
virion
case
latent
nonproduct
infect
viru
activ
produc
bone
marrow
peripher
blood
lymphocyt
detect
convent
mean
howev
felv
genom
present
target
cell
capabl
viral
reactiv
certain
condit
notabl
administr
corticosteroid
rojko
et
al
addit
recent
report
lewi
et
al
lafrado
olsen
indic
neutrophil
defect
occur
rapidli
upon
felv
infect
defect
persist
even
latent
host
defect
observ
neutrophil
isol
felvneg
cat
previous
expos
felv
tabl
neutrophil
lose
abil
form
oxygenfre
radic
thu
lose
abil
kill
invad
organ
latenc
thu
becam
intrigu
test
leukocel
efficaci
vaccin
could
reliabl
protect
cat
latent
infect
valu
prophylact
agent
would
enhanc
consider
test
conduct
norden
laboratori
cat
vaccin
challeng
evalu
viral
latenc
year
viru
challeng
test
cat
receiv
recommend
vaccin
dose
challeng
rickard
strain
felv
felvr
use
procedur
previous
describ
annual
booster
vaccin
singl
dose
also
administ
attempt
activ
latent
felv
month
challeng
methylprednisolon
administ
test
cat
week
consecut
week
rate
mg
immunosuppress
treatment
induc
mean
reduct
lymphocyt
count
indic
immunocompet
test
cat
fact
compromis
cat
experienc
reduct
lymphocyt
count
latenc
assess
cultur
bone
marrow
aspir
obtain
femor
shaft
prior
week
last
immunosuppress
treatment
cultur
maintain
day
cultur
media
contain
hydrocortison
phosphat
shown
consider
enhanc
felv
reactiv
rojko
et
al
presenc
felv
groupspecif
protein
cultur
fluid
determin
elisa
method
cocultiv
plaqu
assay
test
cat
divers
virem
statu
challeng
creat
vari
group
evalu
viru
reactiv
four
cat
avirem
transient
virem
latent
postchalleng
infect
observ
potenti
latent
cat
tabl
even
repeat
immunosuppress
treatment
administ
result
take
ad
signific
view
larg
viral
challeng
burden
infecti
unit
increas
likelihood
latent
infect
use
felvr
challeng
agent
strain
predisposit
toward
viral
latenc
pedersen
et
al
enhanc
cultur
media
hydrocortison
acet
order
promot
viral
reactiv
demonstr
immunosuppress
test
cat
transient
felv
infect
cat
challeng
indic
genom
integr
occur
subsequ
elimin
result
host
immun
respons
approv
obtain
usa
leukocel
administ
subcutan
well
intramuscularli
rout
grant
basi
data
show
subcutan
sc
immun
elicit
tabl
focma
respons
tabl
equival
greater
intramuscular
im
vaccin
mean
vaccin
given
greater
degre
conveni
reduc
patient
discomfort
prototyp
vaccin
test
intramuscular
regimen
rout
administr
convent
patient
discomfort
associ
rout
altern
site
inject
suggest
solut
problem
commerci
prepar
test
effect
given
via
sc
rout
regimen
serolog
respons
gener
compar
im
vaccin
geometr
mean
antifocma
valu
consider
greater
follow
sc
vaccin
im
vaccin
sc
dose
need
produc
strong
focma
antibodi
valu
equal
observ
follow
im
regimen
thu
sc
rout
elicit
antibodi
respons
stronger
rapid
im
respons
appear
rout
administr
inde
affect
immun
respons
antigen
regimen
may
suffici
efficaci
although
manufactur
still
suggest
dose
maxim
effect
experi
suggest
investig
altern
rout
administr
probabl
obligatori
part
vaccin
develop
vaccin
especi
adjuv
prepar
within
month
leukocel
licens
usa
noteworthi
report
appear
attest
vaccin
clinic
perform
highrisk
environ
henbi
et
al
report
confirm
previou
efficaci
studi
use
laboratori
lewi
et
al
sharpe
et
al
addit
studi
perform
independ
practition
administ
felin
leukemia
vaccin
everyday
field
condit
associ
previou
research
convinc
aspect
report
descript
vaccin
coloni
cat
maintain
privat
home
sanit
nutrit
routin
immun
felin
leukemia
observ
owner
coloni
essenti
close
popul
good
health
occasion
contact
stray
cat
august
coloni
cat
experienc
gener
malais
subsequ
die
suspect
felin
leukemia
entir
coloni
subsequ
test
felv
cat
found
felv
posit
cat
coloni
felvposit
felvneg
anim
receiv
dose
leukocel
recommend
interv
two
subsequ
test
felv
week
initi
test
found
felvneg
cat
still
neg
felvposit
cat
remain
posit
durat
observ
period
confirm
coloni
experienc
felin
leukemia
outbreak
neg
cat
remain
contact
felvinfect
cat
four
felvposit
cat
die
test
period
multipl
diagnost
test
confirm
vaccin
cat
remain
felv
neg
despit
nearli
year
continu
unrestrict
physic
contact
includ
common
eat
sleep
facil
felvinfect
cat
perform
vaccin
coloni
take
ad
signific
felvneg
vaccin
geriatr
anim
old
year
thu
fall
one
popul
group
suscept
felv
infect
hardi
report
also
describ
vaccin
cat
second
coloni
public
cat
welfar
shelter
histori
felin
leukemia
prior
vaccin
entir
coloni
cat
elisa
test
felv
felvposit
cat
remov
total
cat
felv
posit
remain
cat
vaccin
dose
leukocel
thereaft
incom
cat
test
felv
statu
prior
entri
coloni
cat
found
neg
vaccin
ad
coloni
purpos
studi
primarili
remov
felv
cat
coloni
abl
maintain
felv
free
although
screen
program
coloni
elimin
major
posit
cat
infect
cat
may
still
enter
shelter
due
falseneg
elisa
test
due
latent
infect
initi
pretest
hold
period
despit
possibl
felv
exposur
open
shelter
larg
transient
popul
vaccin
ensu
month
test
felv
posit
mitig
circumst
possibl
felv
exposur
prior
vaccin
exist
cat
experi
coloni
signific
involv
larg
number
vaccin
extend
period
signific
number
expos
felvinfect
cat
secondli
demonstr
program
diagnost
screen
vaccin
effect
elimin
felin
leukemia
even
facil
histori
diseas
transient
popul
involv
high
risk
exposur
valu
alon
develop
strong
cytotox
respons
also
consid
potenti
protect
respons
first
year
commerci
use
felv
vaccin
success
research
continu
develop
safer
effect
vaccin
also
determin
possibl
side
effect
actual
effect
vaccin
gener
cat
popul
would
hard
access
due
limit
time
avail
preliminari
result
suggest
reduct
felv
diseas
associ
syndrom
expect
addit
success
retroviru
vaccin
cat
popul
model
exist
give
better
access
potenti
vaccin
retrovir
diseas
anim
includ
man
